심부전용 POC 및 LOC 장치 시장 예측 : 검사 유형별, 기술, 최종사용자, 지역별 분석(-2034년)

According to Stratistics MRC, the Global Heart Failure POC and LOC Devices Market is accounted for $164.1 million in 2026 and is expected to reach $655.4 million by 2034 growing at a CAGR of 18.9% during the forecast period. Devices known as point-of-care (POC) and lab-on-a-chip (LOC) have become revolutionary in the treatment of heart failure. Healthcare providers can perform on-the-spot testing with these portable, rapid diagnostic technologies, giving them quick insights into a patient's cardiac health. POC devices, which provide quick and effective diagnostics at the patient's bedside or in primary care settings, include handheld ultrasound devices, portable cardiac biomarker analyzers, and miniaturized lab-on-a-chip platforms.

According to a CDC report from 2018, approximately 655,000 Americans pass away from heart disease each year, making it the leading cause of death in the US (1 in every 4 deaths).

Market Dynamics:

Driver:

Growing heart failure rates

The market for POC and LOC devices is primarily driven by the rising incidence of heart failure, which is linked to aging populations, sedentary lifestyles, and the mounting burden of cardiovascular risk factors. Additionally, globally, the prevalence of heart failure is increasing, which raises the need for diagnostic instruments that can quickly and accurately evaluate cardiac function and support prompt and efficient treatment plans.

Restraint:

Budgetary restrictions and accessibility

The financial limitations pertaining to POC and LOC devices comprise not only the initial acquisition costs but also continuous expenditures like consumables, maintenance, and calibration. Furthermore, patients and healthcare facilities alike are concerned about affordability, especially in environments with limited resources. These advanced diagnostic tools come with a high upfront cost, which could prevent them from being widely adopted, restrict accessibility, and affect how cost-effectively healthcare is delivered.

Opportunity:

Extension of diagnostic expertise

There are numerous opportunities to increase the diagnostic capabilities that POC and LOC devices offer. Sustained technological progress, specifically in domains like biosensors, micro fluidics, and nanotechnology, offers prospects for augmenting the sensitivity and specificity of said apparatus. Moreover, healthcare practitioners can now obtain a deeper and more comprehensive understanding of cardiovascular health thanks to advancements in multiplexed testing and the integration of novel biomarkers.

Threat:

Strong market rivalry

The POC and LOC device market is highly competitive, which poses risks like price pressure, market saturation, and difficulty differentiating products. The pressure to compete is increased by new entrants and ongoing technological advancements. Furthermore, in order to stay competitive, businesses need to make investments in R&D, put effective marketing strategies into practice, and concentrate on developing distinctive value propositions in order to hold onto their market positions and continue growing.

Covid-19 Impact:

The COVID-19 pandemic has had a significant effect on the market for medical diagnostics, particularly point-of-care (POC) and lab-on-a-chip (LOC) devices. Demand for POC and LOC devices has surged due to the pressing need for quick and decentralized testing solutions, especially in the diagnosis of COVID-19. These technological advancements have been essential in improving test accessibility and facilitating prompt results at the point of care. On the other hand, the pandemic has also brought about difficulties like changes in the distribution of healthcare resources, heightened competition, and supply chain disruptions. Moreover, the management of the pandemic has spurred innovation and highlighted the critical role POC and LOC devices play in flexible, decentralized healthcare systems, which will impact the market's future direction in the aftermath of the pandemic.

The Genomic Testing segment is expected to be the largest during the forecast period

The segment of the heart failure POC and LOC devices market that is expected to hold the largest share is genomic testing. A person's DNA is analyzed as part of a genomic test to find genetic variants, mutations, and disease predispositions. The broad applications of this segment in pharmacogenomics, oncology, rare genetic disorders, and personalized medicine have made it more well-known. In order to diagnose, treat, and evaluate disease risk, genomic testing is essential. This results in more specialized and efficient healthcare interventions. Additionally, genomic testing is becoming increasingly popular and is becoming recognized as a major player in the field of molecular diagnostics due to the ongoing improvements in sequencing technologies and the growing knowledge of the genetic causes of various diseases.

The Home Care segment is expected to have the highest CAGR during the forecast period

In the market for heart failure POC and LOC devices, the home care segment is growing at the highest CAGR. Patients receiving home care services receive medical attention, supervision, and support in the comfort of their own homes. A number of factors, such as an aging population, a desire for individualized and patient-centered care, and developments in remote monitoring technologies, have contributed to the rise in demand for home care. In addition to providing patients with convenience, home care services lower healthcare costs by minimizing hospital stays. Moreover, the COVID-19 pandemic has expedited the uptake of home care services as individuals pursue less hazardous substitutes for in-person medical consultations.

Region with largest share:

It is projected that the heart failure POC and LOC device market will have the largest share in the North American region. This is ascribed to elements like high healthcare spending, sophisticated healthcare infrastructure, a solid regulatory base, and a strong emphasis on R&D. With a large healthcare industry footprint, the United States in particular is a major factor contributing to the region's dominance. Furthermore, North America gains from a focus on healthcare accessibility, technological innovation, and an aging population.

Region with highest CAGR:

The market for heart failure POC and LOC devices is growing at the highest CAGR in the Asia-Pacific region. Growing healthcare awareness, rising disposable incomes, growing healthcare infrastructure, and an aging and sizable population are some of the factors driving this explosive growth. Significant investments in healthcare services and technology are being made in APAC nations like China and India, along with encouraging government initiatives. Additionally, the demand for cutting-edge medical treatments and the rising incidence of chronic diseases both support the strong growth in the Asia-Pacific healthcare market.

Key players in the market

Some of the key players in Heart Failure POC and LOC Devices market include Instrumentation Laboratory Company, F. Hoffmann-La Roche Ltd, Abaxis, Inc., Jant Pharmacal Corporation, Danaher Corporation, Siemens Healthineers, Trinity Biotech, Quidel Corporation, Abbott and bioMerieux S.A.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In December 2023, Danaher Corp., a global life sciences and diagnostics provider based in Washington D.C., has completed its $5.7 billion acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. Abcam has become an indirect wholly owned subsidiary of Danaher. Danaher's Life Sciences businesses provide tools and technologies to support the advancement of pharmaceuticals and biopharmaceuticals.

In November 2023, Siemens Healthineers has secured a three-year, $5.5 million contract with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health, to develop a test to improve sepsis treatment.

Test Types Covered:

• Proteomic Testing
• Metabolomic Testing
• Genomic Testing
• Other Test Types

Technologies Covered:

• Microfluidics
• Array-based Systems
• Other Technologies

End Users Covered:

• Clinics & Hospitals
• Home Care
• Assisted Living Healthcare Facilities
• Laboratory
• Specialty Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Heart Failure POC And LOC Devices Market, By Test Type

• 5.1 Introduction
• 5.2 Proteomic Testing
• 5.3 Metabolomic Testing
• 5.4 Genomic Testing
• 5.5 Other Test Types

6 Global Heart Failure POC And LOC Devices Market, By Technology

• 6.1 Introduction
• 6.2 Microfluidics
• 6.3 Array-based Systems
• 6.4 Other Technologies

7 Global Heart Failure POC And LOC Devices Market, By End User

• 7.1 Introduction
• 7.2 Clinics & Hospitals
• 7.3 Home Care
• 7.4 Assisted Living Healthcare Facilities
• 7.5 Laboratory
• 7.6 Specialty Centers
• 7.7 Other End Users

8 Global Heart Failure POC And LOC Devices Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Instrumentation Laboratory Company
• 10.2 F. Hoffmann-La Roche Ltd
• 10.3 Abaxis, Inc.
• 10.4 Jant Pharmacal Corporation
• 10.5 Danaher Corporation
• 10.6 Siemens Healthineers
• 10.7 Trinity Biotech
• 10.8 Quidel Corporation
• 10.9 Abbott
• 10.10 bioMerieux S.A